Raymond James Financial
ELVN icon

Raymond James Financial’s Enliven Therapeutics ELVN Stock Holding History

Raymond James Financial’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,612
Closed -$416K – 5450
2026
Q1 		$416K Buy
+10,612
New +$294K ﹤0.01% 4477

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Raymond James Financial's ELVN Position: Q2 2026 in Review

Raymond James Financial sold out of Enliven Therapeutics (ELVN) in Q2 2026, closing a stake of 10,612 shares — an estimated $416K sold.

Raymond James Financial first reported a position in ELVN in Q1 2026 and held it in 1 quarter. The position peaked at $416K in Q1 2026. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Raymond James Financial reported no remaining Enliven Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Raymond James Financial sold 10,612 Enliven Therapeutics shares in Q2 2026, an estimated $416K.
  • Raymond James Financial first reported a position in Enliven Therapeutics in Q1 2026 and held it in 1 quarter.
  • Raymond James Financial's Enliven Therapeutics position peaked at $416K in Q1 2026.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.